{"id":"intensive-chemotherapy","safety":{"commonSideEffects":[{"rate":"50-90%","effect":"Nausea and vomiting"},{"rate":"30-70%","effect":"Fatigue"},{"rate":"40-80%","effect":"Hair loss"},{"rate":"10-50%","effect":"Infection"},{"rate":"20-40%","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This approach is often used to treat advanced or aggressive cancers, and can involve a combination of different chemotherapy agents. The goal is to induce a complete or partial remission, or to control symptoms and improve quality of life.","oneSentence":"Intensive chemotherapy involves the use of high doses of chemotherapy drugs to kill cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:16:28.144Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of various types of cancer, including leukemia, lymphoma, and solid tumors"}]},"trialDetails":[{"nctId":"NCT04284787","phase":"PHASE2","title":"BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-16","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":60},{"nctId":"NCT06172296","phase":"PHASE3","title":"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-04-19","conditions":"Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":478},{"nctId":"NCT04503694","phase":"PHASE2","title":"Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jules Bordet Institute","startDate":"2021-03-25","conditions":"Rectal Cancer Stage II, Rectal Cancer Stage III","enrollment":72},{"nctId":"NCT04530565","phase":"PHASE3","title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-25","conditions":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":348},{"nctId":"NCT04214249","phase":"PHASE2","title":"BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-17","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":49},{"nctId":"NCT05260528","phase":"PHASE2","title":"CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2023-05-03","conditions":"Acute Myeloid Leukemia","enrollment":248},{"nctId":"NCT07407140","phase":"PHASE3","title":"VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-30","conditions":"AML, Adult","enrollment":300},{"nctId":"NCT07211958","phase":"PHASE3","title":"Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation","status":"RECRUITING","sponsor":"Syndax Pharmaceuticals","startDate":"2025-11-25","conditions":"Acute Myeloid Leukemias","enrollment":468},{"nctId":"NCT07490288","phase":"NA","title":"Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"AML","enrollment":30},{"nctId":"NCT04988555","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)","status":"RECRUITING","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2022-02-28","conditions":"Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma","enrollment":606},{"nctId":"NCT06985485","phase":"PHASE2","title":"Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-05-17","conditions":"Acute Lymphoblastic Leukemia, Immunotherapy, Blinatumomab","enrollment":26},{"nctId":"NCT07485010","phase":"PHASE2","title":"Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial","status":"NOT_YET_RECRUITING","sponsor":"The University of Queensland","startDate":"2027-04","conditions":"Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection, Non-Tuberculous Mycobacterial (NTM) Infections","enrollment":300},{"nctId":"NCT07486726","phase":"PHASE1, PHASE2","title":"Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2026-03-15","conditions":"Acute Myeloid Leukemia (AML), Relapse Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia (AML)","enrollment":112},{"nctId":"NCT06852222","phase":"PHASE3","title":"A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-06-04","conditions":"Leukemia, Myeloid, Acute","enrollment":600},{"nctId":"NCT07372924","phase":"PHASE2","title":"A Trial of Tegileridine Fumarate Lnjection for Prolonged Mechanical Ventilation Abirritation in the Intensive Care Unit (ICU)","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2026-02-24","conditions":"Abirritation in the ICU","enrollment":120},{"nctId":"NCT05735184","phase":"PHASE1","title":"A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML","status":"RECRUITING","sponsor":"Kura Oncology, Inc.","startDate":"2023-07-18","conditions":"Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation, Refractory AML","enrollment":420},{"nctId":"NCT04746235","phase":"PHASE2","title":"Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-02-22","conditions":"Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":85},{"nctId":"NCT05453903","phase":"PHASE1","title":"A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-10-04","conditions":"Leukemia, Myeloid, Acute","enrollment":196},{"nctId":"NCT05834244","phase":"PHASE1","title":"A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-10-26","conditions":"Acute Myeloid Leukemia","enrollment":32},{"nctId":"NCT07463768","phase":"PHASE2","title":"Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy.","status":"NOT_YET_RECRUITING","sponsor":"French Innovative Leukemia Organisation","startDate":"2026-09","conditions":"Acute Myeloid Leukemia","enrollment":60},{"nctId":"NCT06713837","phase":"PHASE3","title":"IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.","status":"RECRUITING","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2025-02-27","conditions":"Acute Myeloid Leukemia, Relapse/Recurrence","enrollment":339},{"nctId":"NCT03226418","phase":"PHASE2","title":"Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2017-07-07","conditions":"Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia","enrollment":75},{"nctId":"NCT06456463","phase":"PHASE2","title":"A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy","status":"RECRUITING","sponsor":"Stemline Therapeutics, Inc.","startDate":"2025-01-14","conditions":"Acute Myeloid Leukemia","enrollment":83},{"nctId":"NCT07350850","phase":"PHASE2","title":"A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Real-World Investigator-Selected Treatment (Observational Cohort)","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-12-25","conditions":"PCNSL, Primary Central Nervous System Lymphoma","enrollment":110},{"nctId":"NCT07060001","phase":"PHASE2","title":"Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker","status":"NOT_YET_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2026-04","conditions":"Acute Myeloid Leukemia (AML), Acute Myeloid Leukaemia (AML)","enrollment":112},{"nctId":"NCT03214562","phase":"PHASE1, PHASE2","title":"Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-09-26","conditions":"High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":116},{"nctId":"NCT00756379","phase":"NA","title":"Century Trial, a Randomized Lifestyle Modification Study for Management of Stable Coronary Artery Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2009-03-11","conditions":"Cardiovascular Disease, Atherosclerosis, Coronary Artery Disease","enrollment":1085},{"nctId":"NCT06253637","phase":"PHASE2","title":"Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2024-10-17","conditions":"T-Lymphocytic Leukemia, Acute","enrollment":31},{"nctId":"NCT06952101","phase":"NA","title":"A Global, Integrated, Personalized, Stage-related, Multimodal Therapeutic Approach for Rectal Adenocarcinoma Based on Organ Sparing and Mininvasivity","status":"RECRUITING","sponsor":"Fondazione del Piemonte per l'Oncologia","startDate":"2024-04-30","conditions":"Rectal Adenocarcinoma, Non Metastatic","enrollment":200},{"nctId":"NCT05520567","phase":"PHASE1, PHASE2","title":"A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2023-01-31","conditions":"Acute Myeloid Leukemia (AML), FLT3-mutated Acute Myeloid Leukemia","enrollment":70},{"nctId":"NCT06789003","phase":"NA","title":"Evaluation of a PREHABilitation Protocol Using Adapted Physical Activity (APA) for Multiple Myeloma Patients Eligible for Intensive Autologous Stem Cell Transplantation Treatment","status":"RECRUITING","sponsor":"Centre Hospitalier Henri Duffaut - Avignon","startDate":"2025-02-10","conditions":"Multiple Myeloma","enrollment":120},{"nctId":"NCT07132684","phase":"PHASE3","title":"Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-08-31","conditions":"AML, Adult","enrollment":240},{"nctId":"NCT03126916","phase":"PHASE3","title":"Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2018-05-14","conditions":"Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":750},{"nctId":"NCT06942039","phase":"EARLY_PHASE1","title":"Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation","status":"RECRUITING","sponsor":"C17 Council","startDate":"2025-09-23","conditions":"CNS Embryonal Tumor, CNS, Medulloblastoma, Atypical Teratoid Rhabdoid Tumor","enrollment":15},{"nctId":"NCT07153796","phase":"PHASE2","title":"A Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-01-30","conditions":"B-cell Acute Lymphoblastic Leukemia","enrollment":60},{"nctId":"NCT06782542","phase":"PHASE2","title":"Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy","status":"RECRUITING","sponsor":"Justin Watts, MD","startDate":"2026-05-01","conditions":"Acute Myeloid Leukemia, IDH1 Mutation","enrollment":16},{"nctId":"NCT02677922","phase":"PHASE1, PHASE2","title":"A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2016-06-03","conditions":"Leukemia, Myeloid, Acute","enrollment":130},{"nctId":"NCT06827288","phase":"NA","title":"Adaptive Interventions for Emergency Department Patients With Opioid Use Disorder","status":"RECRUITING","sponsor":"RAND","startDate":"2024-10-04","conditions":"Opioid Use Disorder","enrollment":500},{"nctId":"NCT06226571","phase":"PHASE1","title":"A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias","status":"RECRUITING","sponsor":"Syndax Pharmaceuticals","startDate":"2024-05-21","conditions":"Acute Myeloid Leukemias","enrollment":76},{"nctId":"NCT07407660","phase":"PHASE3","title":"Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus Venetoclax","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2026-02-01","conditions":"Acute Myeloid Leukemia","enrollment":250},{"nctId":"NCT02875314","phase":"PHASE4","title":"HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Parth Patel","startDate":"2015-09","conditions":"Medulloblastoma, Central Nervous System Embryonal Tumors","enrollment":250},{"nctId":"NCT03165851","phase":"","title":"Efficacy Analysis of Comparison of CAMS（Chinese Academy of Medical Sciences）-2005 Trial and CAMS-2009 Trial for Pediatric Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2005-04-10","conditions":"Acute Myeloid Leukemia, Pediatric","enrollment":320},{"nctId":"NCT05536908","phase":"NA","title":"Evaluating Supplementing Residential Substance Use Treatment With Written Exposure Therapy for Veterans With Post Traumatic Stress Disorder (PTSD) and Substance Use Disorders (SUD)","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2023-06-22","conditions":"PTSD, Substance Use Disorders","enrollment":56},{"nctId":"NCT02662504","phase":"PHASE2","title":"Intrapleural Photodynamic Therapy in a Multimodal Treatment for Patients With Malignant Pleural Mesothelioma","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2016-01-16","conditions":"Malignant Pleural Mesothelioma","enrollment":6},{"nctId":"NCT07172204","phase":"PHASE2","title":"Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-09-16","conditions":"Intensive Chemotherapy Unfit, Newly Diagnosed Acute Myeloid Leukemia (AML), Age ≥60","enrollment":25},{"nctId":"NCT01175356","phase":"PHASE1","title":"Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2011-12-21","conditions":"Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma","enrollment":99},{"nctId":"NCT00336024","phase":"PHASE3","title":"Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2007-10-22","conditions":"Anaplastic Medulloblastoma, Medulloblastoma, Supratentorial Embryonal Tumor, Not Otherwise Specified","enrollment":91},{"nctId":"NCT05001828","phase":"PHASE1","title":"Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Polaris Group","startDate":"2022-04-05","conditions":"Acute Myeloid Leukemia, Adult","enrollment":38},{"nctId":"NCT03701308","phase":"PHASE2, PHASE3","title":"Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-03-28","conditions":"Acute Myeloid Leukemia","enrollment":267},{"nctId":"NCT07222579","phase":"PHASE2","title":"Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL)","status":"RECRUITING","sponsor":"West Virginia University","startDate":"2026-02","conditions":"CD19 Positive, Mixed Phenotype Acute Leukemia (MPAL)","enrollment":78},{"nctId":"NCT03709758","phase":"PHASE1","title":"Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2018-10-17","conditions":"Acute Myeloid Leukemia","enrollment":50},{"nctId":"NCT07343687","phase":"","title":"Clinico-hematological and Coagulation Profiles in Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Intensive Induction Chemotherapy .","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-02","conditions":"Acute Myeloid Leukemia","enrollment":80},{"nctId":"NCT07336914","phase":"NA","title":"Effect of Conventional vs Intensive Management on Gestational Diabetes and Maternal Fetal Outcomes","status":"RECRUITING","sponsor":"Khyber Medical University Peshawar","startDate":"2025-10-01","conditions":"Gestational Diabetes","enrollment":60},{"nctId":"NCT05023317","phase":"PHASE1","title":"Strengths-based Linkage to Alcohol Care (SLAC) for Hazardous Drinkers in Primary Care","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2021-01-01","conditions":"Alcohol-induced Disorders, Alcohol Drinking, Mental Health","enrollment":140},{"nctId":"NCT07335094","phase":"EARLY_PHASE1","title":"A Clinical Study of Humanized CD19 CAR-T Cells With TLR2 for the Treatment of Adult Patients With Naive B-Cell Acute Lymphoblastic Leukemia/Lymphoma Who Are Intolerant to Intensive Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Zhujiang Hospital","startDate":"2026-06-01","conditions":"B Lymphoblastic Leukemia/Lymphoma","enrollment":60},{"nctId":"NCT05342584","phase":"PHASE1","title":"Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS","status":"RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2022-05-25","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":99},{"nctId":"NCT03756961","phase":"NA","title":"Effects of an Opioid Free/Sparing Care Pathway for Patients Undergoing Obesity Surgery","status":"RECRUITING","sponsor":"Göteborg University","startDate":"2019-05-01","conditions":"Obesity, Pain, Postoperative","enrollment":220},{"nctId":"NCT07305350","phase":"PHASE2","title":"EFFICACY OF MELATONIN IN MANAGEMENT OF HYPOXIC ISCHEMIC ENCEPHALOPATHY (HIE) IN NEONATES","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Child Health Sciences and Children's Hospital, Lahore","startDate":"2025-12-10","conditions":"Hypoxic Ischaemic Encephalopathy (HIE)","enrollment":110},{"nctId":"NCT05996185","phase":"PHASE2","title":"Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma","status":"RECRUITING","sponsor":"Yale University","startDate":"2024-10-09","conditions":"T Cell Lymphoma, T-cell Lymphoma","enrollment":22},{"nctId":"NCT05091684","phase":"PHASE2","title":"Administration of Fibrinogen Concentrate for Refractory Bleeding","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2022-02-10","conditions":"Hematological Patients, Bleeding, Platelet Refractoriness","enrollment":1},{"nctId":"NCT03013998","phase":"PHASE1, PHASE2","title":"Study of Biomarker-Based Treatment of Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Beat AML, LLC","startDate":"2016-11","conditions":"Previously Untreated Relapsed Refractory Acute Myeloid Leukemia","enrollment":3000},{"nctId":"NCT06030089","phase":"NA","title":"Plasma Dosage of Venetoclax in the Fup of AML Patients Treated With Aza + Ven","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2024-02-26","conditions":"Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT01869114","phase":"PHASE2","title":"Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2013-07-08","conditions":"Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)","enrollment":57},{"nctId":"NCT05215639","phase":"","title":"A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy in Switzerland and Austria Receiving Oral Venetoclax Tablets","status":"COMPLETED","sponsor":"AbbVie","startDate":"2021-12-27","conditions":"Acute Myeloid Leukemia","enrollment":120},{"nctId":"NCT06782971","phase":"","title":"Evaluation of Combined Sensitising and Hypomethylating Therapy Outcomes in AML PDX","status":"RECRUITING","sponsor":"Clinical Hub for Interventional Research (CHOIR)","startDate":"2025-06-06","conditions":"AML - Acute Myeloid Leukemia","enrollment":25},{"nctId":"NCT07269132","phase":"NA","title":"Applying the ADDIE Model to Develop a Multimedia Program to Enhance Chemotherapy Knowledge and Self-Efficacy Among Intensive Care Unit Nurses","status":"ENROLLING_BY_INVITATION","sponsor":"National Cheng-Kung University Hospital","startDate":"2025-11-01","conditions":"Nurse, Self-Efficacy, eLearning","enrollment":50},{"nctId":"NCT00846742","phase":"PHASE2","title":"Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2009-06-05","conditions":"Hodgkin Lymphoma","enrollment":88},{"nctId":"NCT07258043","phase":"","title":"Efficacy of Dose-Adjusted Regimen on Survival in Frail Adults With Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Hospital General de Mexico","startDate":"2025-07-23","conditions":"Acute Lymphobkastic Leukemia, Leukemia, Overall Survival","enrollment":45},{"nctId":"NCT05424562","phase":"","title":"A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2022-09-07","conditions":"Acute Myeloid Leukemia","enrollment":210},{"nctId":"NCT05566054","phase":"PHASE2","title":"Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2022-03-01","conditions":"Acute Monocytic Leukemia, Newly Diagnosed","enrollment":92},{"nctId":"NCT06532552","phase":"PHASE2","title":"Comparison of VA (Venetoclax, Azacitidine), VACl (VA, Cladribine), VACh (VA, Chidamide), and Alternating VACl/VACh in Newly Diagnosed Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-07-29","conditions":"Acute Myeloid Leukemia, Adult, Newly Diagnosed","enrollment":172},{"nctId":"NCT07236931","phase":"NA","title":"Clinical Study of Selinexor-Based Chemotherapy With Minimal or No Cytotoxic Agents in Treatment-Naïve AML Patients Unsuitable for Intensive Therapy: Focusing on Rapid Reduction of Blast Cells","status":"NOT_YET_RECRUITING","sponsor":"Donghua Zhang","startDate":"2025-11-20","conditions":"AML (Acute Myeloid Leukemia)","enrollment":71},{"nctId":"NCT06472128","phase":"NA","title":"Novel Digital Application for Patients With Acute Leukemia","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-10-21","conditions":"Relapsed Adult Acute Myeloid Leukemia, Primary Refractory Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia","enrollment":200},{"nctId":"NCT07223814","phase":"PHASE3","title":"Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)","status":"NOT_YET_RECRUITING","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2025-12","conditions":"Acute Myeloid Leukemia","enrollment":875},{"nctId":"NCT06549790","phase":"PHASE1","title":"Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Nerviano Medical Sciences","startDate":"2024-10-16","conditions":"Relapsed/Refractory Acute Myeloid Leukemia","enrollment":124},{"nctId":"NCT04266795","phase":"PHASE2","title":"A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy","status":"COMPLETED","sponsor":"Takeda","startDate":"2020-10-13","conditions":"Acute Myeloid Leukemia (AML)","enrollment":164},{"nctId":"NCT03513484","phase":"PHASE1","title":"Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwestern University","startDate":"2018-11-14","conditions":"Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A, Fibroblast Growth Factor Basic Form Measurement, FLT3 Internal Tandem Duplication","enrollment":44},{"nctId":"NCT07207980","phase":"NA","title":"Lifestyle Intervention for Type 2 Diabetes in Primary Care (CREDOenAP)","status":"NOT_YET_RECRUITING","sponsor":"Parc Sanitari Pere Virgili","startDate":"2026-01-11","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":120},{"nctId":"NCT07014462","phase":"PHASE1","title":"A Phase 1B Investigator Initiated Study of Safety and Tolerability of Dexamethasone (D) in Combination With Venetoclax-based Low-Intensity Therapy (LIT) in Treatment-Naïve Acute Myeloid Leukemia (AML): DLIT-AML","status":"ENROLLING_BY_INVITATION","sponsor":"University of Vermont","startDate":"2025-09-01","conditions":"AML - Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT04777916","phase":"","title":"Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)","status":"RECRUITING","sponsor":"Acute Leukemia French Association","startDate":"2022-04-14","conditions":"Acute Myeloid Leukemia (AML)","enrollment":5000},{"nctId":"NCT03069352","phase":"PHASE3","title":"A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-05-23","conditions":"Acute Myeloid Leukemia (AML)","enrollment":211},{"nctId":"NCT06409767","phase":"NA","title":"Impact of an Early Warning System on the Prognosis of Patients With Hematological Malignancies Receiving Intensive Chemotherapy With or Without Hematopoietic Cell Transplantation.","status":"RECRUITING","sponsor":"University Hospital, Angers","startDate":"2025-04-10","conditions":"Leukemia, Lymphoma, Multiple Myeloma","enrollment":2224},{"nctId":"NCT05132244","phase":"NA","title":"Monitoring and Managing Glucose Levels in People With Pancreatic Cancer","status":"RECRUITING","sponsor":"British Columbia Cancer Agency","startDate":"2024-04-16","conditions":"Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Hyperglycemia","enrollment":50},{"nctId":"NCT06668558","phase":"PHASE2","title":"Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias","startDate":"2024-12-16","conditions":"Acute Myeloid Leukemia","enrollment":29},{"nctId":"NCT05191446","phase":"NA","title":"Coronavirus Disease 2019 (Covid-19) Impact on Alcohol-related Liver Disease Patient Outcomes, Care and Alcohol Use","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2022-02-01","conditions":"Liver Diseases, Alcohol Use Disorder","enrollment":180},{"nctId":"NCT07179120","phase":"PHASE2","title":"Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm Health","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2026-05-01","conditions":"Obesity-related Male Infertility","enrollment":180},{"nctId":"NCT06621212","phase":"PHASE2","title":"Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-07-05","conditions":"Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy","enrollment":72},{"nctId":"NCT02752035","phase":"PHASE3","title":"A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2016-08-01","conditions":"Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation","enrollment":183},{"nctId":"NCT07168980","phase":"PHASE2, PHASE3","title":"Chemotherapy With Rituximab for Aggressive B-NHL in Children and Adolescents","status":"RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2025-07-01","conditions":"Mature B-cell Non-Hodgkin Lymphoma","enrollment":87},{"nctId":"NCT07149909","phase":"NA","title":"Fiberoptic Bronchoscopy in Severe Ventilator-associated Pneumonia","status":"COMPLETED","sponsor":"Benha University","startDate":"2023-12-15","conditions":"Ventilator-Associated Pneumonia, Severe Pneumonia, Critical Illness","enrollment":100},{"nctId":"NCT06490536","phase":"PHASE3","title":"The Sagittarius Trial","status":"RECRUITING","sponsor":"IFOM ETS - The AIRC Institute of Molecular Oncology","startDate":"2024-10-22","conditions":"Colon Cancer Stage II, Colon Cancer Stage III","enrollment":700},{"nctId":"NCT07143877","phase":"","title":"Prognostic Impacts of Lipid Profile and BMI in Adult AML","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-11-15","conditions":"AML (Acute Myeloid Leukemia), BMI, Lipid Profile","enrollment":200},{"nctId":"NCT04023526","phase":"PHASE2","title":"A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"OncoVerity, Inc.","startDate":"2019-07-29","conditions":"Leukemia, Myeloid, Acute","enrollment":103},{"nctId":"NCT07075016","phase":"PHASE3","title":"Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy","status":"RECRUITING","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2025-08-05","conditions":"Acute Myeloid Leukemia","enrollment":227},{"nctId":"NCT03054896","phase":"PHASE2","title":"A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-03-08","conditions":"Richter Syndrome","enrollment":69},{"nctId":"NCT04310930","phase":"PHASE2, PHASE3","title":"Finding the Optimal Regimen for Mycobacterium Abscessus Treatment","status":"RECRUITING","sponsor":"The University of Queensland","startDate":"2020-03-02","conditions":"Pulmonary Disease Due to Mycobacteria (Diagnosis)","enrollment":300},{"nctId":"NCT05144243","phase":"PHASE4","title":"Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2022-01-06","conditions":"Acute Myeloid Leukemia (AML)","enrollment":44},{"nctId":"NCT03405870","phase":"PHASE1, PHASE2","title":"LIPIDS-P Trial Phase I/II Trial","status":"COMPLETED","sponsor":"University of Florida","startDate":"2018-08-17","conditions":"Sepsis, Severe, Septic Shock","enrollment":59},{"nctId":"NCT06386302","phase":"NA","title":"Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-08-05","conditions":"AML, Acute Myeloid Leukemia","enrollment":184},{"nctId":"NCT03897127","phase":"PHASE3","title":"Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Ulm","startDate":"2019-09-04","conditions":"Acute Myeloid Leukemia","enrollment":882}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"intensive chemotherapy","genericName":"intensive chemotherapy","companyName":"University Hospital, Toulouse","companyId":"university-hospital-toulouse","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Intensive chemotherapy involves the use of high doses of chemotherapy drugs to kill cancer cells. Used for Treatment of various types of cancer, including leukemia, lymphoma, and solid tumors.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}